These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14576153)

  • 1. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.
    Lu D; Zhang H; Ludwig D; Persaud A; Jimenez X; Burtrum D; Balderes P; Liu M; Bohlen P; Witte L; Zhu Z
    J Biol Chem; 2004 Jan; 279(4):2856-65. PubMed ID: 14576153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
    Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
    MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
    Lu D; Zhang H; Koo H; Tonra J; Balderes P; Prewett M; Corcoran E; Mangalampalli V; Bassi R; Anselma D; Patel D; Kang X; Ludwig DL; Hicklin DJ; Bohlen P; Witte L; Zhu Z
    J Biol Chem; 2005 May; 280(20):19665-72. PubMed ID: 15757893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
    J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Iacolina M; Zhang H; Zhu Z
    J Biol Chem; 2006 Apr; 281(16):10706-14. PubMed ID: 16481314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.
    Jarantow SW; Bushey BS; Pardinas JR; Boakye K; Lacy ER; Sanders R; Sepulveda MA; Moores SL; Chiu ML
    J Biol Chem; 2015 Oct; 290(41):24689-704. PubMed ID: 26260789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
    Shen Y; Zeng L; Novosyadlyy R; Forest A; Zhu A; Korytko A; Zhang H; Eastman SW; Topper M; Hindi S; Covino N; Persaud K; Kang Y; Burtrum D; Surguladze D; Prewett M; Chintharlapalli S; Wroblewski VJ; Shen J; Balderes P; Zhu Z; Snavely M; Ludwig DL
    MAbs; 2015; 7(5):931-45. PubMed ID: 26073904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer.
    Schanzer JM; Wartha K; Moessner E; Hosse RJ; Moser S; Croasdale R; Trochanowska H; Shao C; Wang P; Shi L; Weinzierl T; Rieder N; Bacac M; Ries CH; Kettenberger H; Schlothauer T; Friess T; Umana P; Klein C
    MAbs; 2016; 8(4):811-27. PubMed ID: 26984378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
    Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
    Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
    MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.
    Sellmann C; Doerner A; Knuehl C; Rasche N; Sood V; Krah S; Rhiel L; Messemer A; Wesolowski J; Schuette M; Becker S; Toleikis L; Kolmar H; Hock B
    J Biol Chem; 2016 Nov; 291(48):25106-25119. PubMed ID: 27694443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.
    Ploeg EM; Samplonius DF; Xiong X; Ke X; Hendriks MAJM; Britsch I; van Wijngaarden AP; Zhang H; Helfrich W
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37734877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity.
    Chen Z; Xie W; Acheampong DO; Xu M; He H; Yang M; Li C; Luo C; Wang M; Zhang J
    Cancer Biol Ther; 2016; 17(2):139-50. PubMed ID: 26671532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.